Market Cap (In KRW)
1322.92 Billion
Revenue (In KRW)
65.54 Billion
Net Income (In KRW)
-2.64 Billion
Avg. Volume
2.01 Million
- Currency
- KRW
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 18960.0-43300.0
- PE
- -
- EPS
- -
- Beta Value
- 1.009
- ISIN
- KR7298380007
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Dr. Sang Hoon Lee Ph.D.
- Employee Count
- -
- Website
- http://www.ablbio.com
- Ipo Date
- 2018-12-19
- Details
- ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.
More Stocks
-
BPCGF
-
KPIGREENKPI Green Energy Limited
KPIGREEN
-
1938
-
HYDHydrix Limited
HYD
-
BANKBARODABank of Baroda Limited
BANKBARODA
-
GNHRFArian Resources Corp.
GNHRF
-
000719
-
TOAGFToagosei Co., Ltd.
TOAGF